|
[posting]44903911[/posting]News resp. Partner wird auch für den SGLT2 Inhibitors von Sirona erwartet. Produkt ist besser als SGLT2 Inhibitors A New Class of Diabetes Drugs SGLT2 inhibitor’s NOVEL mechanism of action blocks re-uptake of glucose from the kidney and may also improve obesity profile. Markt: More than 371 million people have diabetes. By 2030, this will rise to 552 million. Last year, 4.6 million people died due to diabetes or related complications and more than $471 billion US were spent on healthcare for diabetes. Global prevalence is drastically increasing. mehr Infos: http://www.sironabiochem.com/wp-content/uploads/2013/05/SBM-… |
|
| aus der Diskussion: | Sirona Biochem |
| Autor (Datum des Eintrages): | Jon_Schnee (23.06.13 13:13:01) |
| Beitrag: | 4 von 31,047 (ID:44903967) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |